COMMUNIQUÉS West-GlobeNewswire

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
01/07/2026
NAARDEN, the Netherlands and MIAMI, July 01, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
01/07/2026
The nonclinical study conducted at Stony Brook University adds to substantial evidence of activity across multiple animal models of neuropathic pain SOLANA BEACH, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Artelo [...]
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
01/07/2026
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS , priced at a [...]
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
01/07/2026
Expands Harrow's Growing Retina Portfolio with an Interchangeable Ranibizumab Biosimilar NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management [...]
Seer Prevails in European Patent Opposition as U.S. ITC Opens Investigation into Nanomics
01/07/2026
Seer's particle-based proteomics IP withstands challenges in both Europe and the United States REDWOOD CITY, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, [...]
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
01/07/2026
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months Ramat Gan, Israel, [...]
Human Appeal supports Syrian farmers through new wheat supply chain project
01/07/2026
The initiative will help more than 1,000 farmers across northwest Syria rebuild livelihoods, strengthen food security and restore agricultural production as they return to their communities MISSION VIEJO, Calif., July [...]
Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares
01/07/2026
Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares Le montant de l'offre a été augmenté de 600 M$ à 800 M$ , à un prix de 125,00 $ par ADS , [...]
Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
01/07/2026
Medical Segment Momentum Accelerates, Posting 300% Growth Versus Q2 2025 Company to Showcase Technology at American Society of Pain & Neuroscience Conference in Miami Beach, July 16–18, Alongside Board Member and [...]
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
01/07/2026
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its [...]
FOXO TECHNOLOGIES INC. ANNOUNCES COMPLETION OF REVERSE STOCK SPLIT
01/07/2026
WEST PALM BEACH, FLORIDA, July 01, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “ Company ”), today announced that its previously approved reverse stock split (the “Reverse Split”) of its [...]
Alvotech further strengthens liquidity by securing term loan facility of $75 million
01/07/2026
— $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management — Follows recent $165m equity raise strengthening cash position — Including equity financing and undrawn loan [...]
Oxford-Harrington Rare Disease Centre Strengthens Rare Childhood Cancer Programme Through Appointment of New Little Princess Trust Professor of Paediatric Oncology
01/07/2026
Professor Isidro Cortés-Ciriano, a n internationally recognised scientist with extensive experience in childhood cancer research, will accelerate Oxford-Harrington’s mission to translate discoveries into new therapies [...]
Alvotech further strengthens liquidity by securing term loan facility of $75 million
01/07/2026
$75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management Follows recent $165m equity raise strengthening cash position Including equity financing and undrawn loan facility [...]
AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2026
01/07/2026
COMMUNIQUE DE PRESSE RESULTATS DE L’ASSEMBLEE GENERALE MIXTE DU 30 JUIN 2026 Paris, 1 er juillet 2026, 10h Les actionnaires de la société AB Science se sont réunis en Assemblée Générale Mixte, le mardi 30 juin 2026 à [...]
Press Release: Availability of the aide-mémoire for Q2 2026 results
01/07/2026
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026 . Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter [...]
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
01/07/2026
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a [...]
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
01/07/2026
Abivax annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris PARIS, France, 1 er juillet 2026 – 07h30 CEST – Abivax SA (Euronext Paris : FR0012333284 – ABVX) (« Abivax » ou la « Société [...]
Idorsia appoints Roland Wandeler as Chief Executive Officer
01/07/2026
Ad hoc announcement pursuant to Art. 53 LR Idorsia appoints Roland Wandeler as CEO – effective October 1, 2026 – an experienced biopharmaceutical executive combining scientific expertise with business acumen to [...]

Pages